Trials / Recruiting
RecruitingNCT07220603
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- PepGen Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PGN-EDODM1 | Administered by intravenous (IV) infusion |
Timeline
- Start date
- 2025-12-23
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2025-10-24
- Last updated
- 2026-03-30
Locations
3 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07220603. Inclusion in this directory is not an endorsement.